Get Soligenix alerts:Soligenix Inc. (NASDAQ:SNGX – Free Report) – Zacks Small Cap boosted their Q3 2025 earnings per share estimates for shares of Soligenix in a report released on Tuesday, September 30th. Zacks Small Cap also issued estimates for Soligenix’s Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($3.02) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at ($1.50) EPS. Soligenix (NASDAQ:SNGX – Get Free Report) last released its earnings results on Thursday, August 14th. Institutional Investors Weigh In On SoligenixAn institutional investor recently raised its position in Soligenix stock. Soligenix Company Profile(Get Free Report)Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.